FDA Extends Wyeth, Progenics NDA Review For Methylnaltrexone Until April
Additional three months of review will push methylnaltrexone action date behind GSK/Adolor’s Entereg.
Additional three months of review will push methylnaltrexone action date behind GSK/Adolor’s Entereg.